Abstract Interactions between sodium and calcium regulating systems are poorly characterized but clinically important. Parathyroid hormone (PTH) levels are increased shortly after furosemide treatment by an unknown mechanism, and this effect is blunted by the previous administration of a calcimimetic in animal studies. Here, we explored further the possible underlying mechanisms of this observation in a randomized crossover placebo-controlled study performed in 18 human males. Volunteers took either cinacalcet (60 mg) or placebo and received a 20 mg furosemide injection 3 h later. Plasma samples were collected at 15-min intervals and analyzed for intact PTH, calcium, sodium, potassium, magnesium, phosphate, plasma renin activity (PRA), and aldosterone up to 6 h after furosemide injection. Urinary electrolyte excretion was also monitored. Subjects under placebo presented a sharp increase in PTH levels after furosemide injection. In the presence of cinacalcet, PTH levels were suppressed and marginal increase of PTH was observed. No significant changes in electrolytes and urinary excretion were identified that could explain the furosemide-induced increase in PTH levels. PRA and aldosterone were stimulated by furosemide injection but were not affected by previous cinacalcet ingestion. Expression of NKCC1, but not NKCC2, was found in parathyroid tissue. In conclusion, our results indicate that furosemide acutely stimulates PTH secretion in the absence of any detectable electrolyte changes in healthy adults. A possible direct effect of furosemide on parathyroid gland needs further studies.
Introduction
Several experimental and clinical studies have reported that furosemide increases plasma parathyroid hormone (PTH) after acute or chronic furosemide treatment [6, 10, 18] . As of today, the precise mechanism whereby furosemide stimulates PTH remains largely unknown. Increased calciuria induced by furosemide has been proposed as a possible explanation for this phenomenon, but how calciuria can actually stimulate PTH secretion is obscure, as no significant change in serum calcium has been reported so far [6, 27] . Thus, alternative mechanisms should be considered in order to explain the effect of furosemide on PTH secretion.
If the mechanism remains unknown, furosemide-induced PTH secretion has well-recognized consequences which have been observed in animals and humans [13, 24, 30] . Indeed, rats develop nephrocalcinosis only a few days after the beginning of a furosemide treatment [24] , and chronic administration of furosemide has been associated with the development of nephrocalcinosis in neonates and infants [13, 30] . Moreover, increasing evidence, in human adults, show that furosemide may also cause medullary nephrocalcinosis in a dosedependent manner [17] . Interestingly, nephrocalcinosis did not occur in parathyroidectomized rats treated by furosemide in a preliminary study by Alon et al. [25] . An indirect argument in favor of PTH implication in the nephrocalcinosis observed in furosemide-treated rats is the recent observation that simultaneous administration of furosemide and a calcimimetic blunts this effect [18] . Indeed, NPS R-467, a calcimimetic, is preventing nephrocalcinosis in young rats [25] , further emphasizing the contribution of PTH rather than calciuria in inducing nephrocalcinosis after furosemide treatment. These recent findings also point to a possible role of the calciumsensing receptor as a potential mediator of the effect of furosemide on PTH. Accordingly, we and others have reported that the administration of a calcimimetic to mice and rats decreases the activity of the renin-angiotensin system (RAS) and blunts the furosemide-induced increase of PTH and renin [18] , suggesting that the renin-angiotensin-aldosterone might also be involved. As of today, most of the observations made with calcimimetics have been done in animals, and whether they occur similarly in humans has not been investigated.
This randomized placebo-controlled crossover study was designed to investigate the mechanisms mediating the acute effect of a single dose of furosemide on PTH in healthy adult males. In addition, we have assessed a possible interaction between cinacalcet, renin, aldosterone, and PTH in response to furosemide.
Subjects and methods
The study was conducted on healthy volunteers, recruited through advertisements in the Lausanne University Hospital and at the Lausanne University and Federal Polytechnical School sites. Informed consent was obtained from all individual participants included in the study.
Eighteen Caucasian males aged 18 to 45 years, nonsmokers, and with no concomitant treatment were enrolled in the study. To be included, they should have had, at the screening visit, a BMI >18 and <25 kg/m 2 , normal clinical examination, normal 12-lead ECG, normal blood pressure (<140/90 mmHg), and heart rate (HR)≥45 and ≤90 beats/ min after 5 min in supine position measured three times at 2-min intervals on the left arm. Finally, the subjects had to be able to understand the written information and the written consent form and must have given written, dated, and signed consent before starting any trial procedure.
We excluded subjects with electrolyte disturbances, positive serology for HIV, HBV, or HCV, positive detection of drugs in urine, any history of diseases or clinically significant conditions, and drug therapy.
All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments. The protocol was submitted and approved by the ethical committee of the Canton de Vaud, Switzerland, and the Swiss drug authority BSwissmedic.^The study was registered at ClinicalTrial.gov (ID NCT01519037).
Study protocol
The protocol included two similar 4-day periods with 3 days (D-3 to D-1) of run-in and 1 day of investigation (D0). According to the crossover design, subjects were randomly assigned to receive, in a blinded manner, either a single dose of 60 mg cinacalcet or placebo, orally, in the first and second period respectively. From D-3 to D-1, the volunteers were asked to ingest a low-salt diet in order to achieve a salt intake of <3 g/24 h (50 mmol of Na + per day). This was done to standardize salt intake and to stimulate the renin-angiotensin system. Compliance to the diet was verified using repeated 24-h urine collections.
The investigation day (D0) started at 07:45 with a brief clinical health check. Subjects were asked to empty their bladder, and then, a venous catheter was inserted in a forearm vein for repeated blood samplings. Participants remained in supine position for the whole day, except for voiding. Blood draw was always performed before voiding. Heart rate (HR) and blood pressure (BP) were measured every 30 min (every 15 min during the first hour after furosemide administration). A standardized hydration protocol (2 ml/kg of water every hour) was used all along the day. At 08:00 (H-3), participants received either placebo or 60 mg cinacalcet with a light breakfast. The medication was prepared by the hospital pharmacy and was blinded to both, investigators and subjects. Twenty milligrams of furosemide was injected intravenously immediately after the 11:00 urine collection. BP and HR were measured every 15 min during 1 h after iv furosemide injection. The following parameters were monitored in blood (every 15 min): sodium, potassium, total calcium, ionized calcium, albumin, magnesium, and phosphate, and in urine (every 15-30 min): sodium, potassium, total calcium, creatinine, uric acid, and urea. The samples were immediately processed, aliquoted, and frozen.
Thirteen subjects completed the protocol as indicated above (and are called furosemide positive (F+)). A second cluster of five participants following the same design was added afterwards without administration of furosemide in order to assess the spontaneous variations in PTH levels and are described as Bfurosemide negative (F−)^. According to the crossover design of the study, four subgroups were analyzed, i.e., the cinacalcet/furosemide positive (C/F+) and placebo/ furosemide positive (P/F+) (n = 13) and cinacalcet/ furosemide negative (C/F−) and placebo/furosemide negative (P/F−) (n=5). In the F+ group, six volunteers were assigned first to cinacalcet then to placebo. In the F− group, three participants received cinacalcet first.
Laboratory analysis Urine and blood samples were measured at the Central Chemical Laboratory of the Lausanne University Hospital (CHUV, Lausanne, Vaud, Switzerland) using standard methods.
Serum sodium (intra-and inter-batch CV: 0.20 and 0.90 %, respectively), urine sodium (0.30 and 0.60 %), serum potassium (0.20 and 0.90 %), and urine potassium (0.40 and 0.90 %) were measured by indirect potentiometry (Roche Diagnostics, Switzerland). Ionized calcium (0.80 and 0.60 %) was measured by direct potentiometry (ABL 800, Radiometer Medical). Intact PTH was assessed by immunoassay (Immulite, Siemens). Plasma renin activity was measured by radioimmunoassay of generated concentration of angiotensin I using a commercial kit (RENCTK®; DiaSorin Inc., Stillwater, MN, USA). Measurement of aldosterone in the blood was performed with a commercial RIA (Coat-A-Count® Aldosterone kit, Siemens Medical Solutions Diagnostics; Los Angeles, CA, USA).
Expression of NKCC1 and NKCC2 in parathyroid tissue
Total messenger RNA (mRNA) was obtained from human parathyroid adenoma tissue (CR559081, OriGene, Rockville, MD, USA). One microgram of RNA was reverse-transcribed (PrimeScript RT reagent kit, Takara Bio Inc.) according to the manufacturer's instructions. TaqMan Gene Expression Assays (Applied Biosystems) were used to detect NKCC1, NKCC2, PTH, PTHR1, and actin, and quantitative real-time PCRs were carried out on an ABI PRISM 7500 equipment (Applied Biosystems, Carlsbad, CA) in triplicate for each sample, using TaqMan Universal PCR Master Mix (Applied Biosystems) in a final volume of 20 μl. Results are expressed as relative values to actin and to PTH using the 2 −ΔΔCT method.
Statistics

Sample size calculation
Stata 12 (StataCorp LP, Texas, USA) was used prior to the study for power and sample size calculation as well for the statistical analysis of the results. The hypothesis of this study was based on the assumption that the calcimimetic blunts the PTH response to furosemide. Thus, the power of the study was calculated based on the changes in plasma PTH in the different groups. The increase in PTH levels after furosemide was assumed to have a normal distribution; the sample size calculation was therefore based on two-sample t test. Our hypothesis was an almost twofold basal change of PTH after furosemide in control group as observed in animals (i.e., in terms of absolute values of PTH, an increase of 30 ng/l from 30 to 60 ng/l). In the other group where the subjects were pretreated with cinacalcet, basal PTH is assumed to be decreased by 80 % compared to placebo and is expected to reach about 6 ng/l before furosemide stimulation and 12 ng/l after. Standard deviation of 75 % of these increased values was used in the calculation. Based on these hypotheses with 12 evaluable subjects, the study has 90 % power to detect a change of this magnitude at a 5 % significance level (two-sided).
Analysis of the data revealed that there was neither sequence nor crossover effect. There was no significant difference in baseline characteristics between participants beginning with cinacalcet and the others.
Data are reported as mean±SD or as median and interquartile range when appropriate. Comparisons between the different treatment groups were performed by analysis of the area under the curve and Wilcoxon rank test. A p value less than 0.05 was considered significant.
Because the limit of quantification (LOQ) of iPTH at 3 ng/l was higher than levels measured in the majority of samples harvested in subjects treated with cinacalcet, the levels of iPTH in these latter samples were fixed at 1.5 ng/l for analysis, which is half of LOQ, a common strategy to replace censored data in distribution. This way to substitute censored data is rather conservative but also decreases variability. Therefore, nonparametric tests were used to compare iPTH between groups.
Results
Thirteen subjects received cinacalcet (C) or placebo (P) at baseline (H-3) and furosemide (F+) 3 h later at H0 (C/F+ and P/F+ groups), while five subjects followed the same protocol, but without receiving furosemide (P/F− and C/F− groups). There was no difference in terms of age (27±5 vs 23±4 years), BMI (22.0±2.0 vs 21.8±1.7 kg/m 2 ), systolic blood pressure (122±13 vs 127±5 mmHg), diastolic blood pressure (70±8 vs 65±7 mmHg), and heart rate (66±12 vs 66±12 bpm) at inclusion visit between the 13 volunteers subjected to furosemide injection and the five individuals who did not receive furosemide.
Baseline clinical characteristics of the subjects and the results of the baseline 24 h urine collection are shown in Table 1 . All values were within normal range, and there was no significant difference between the groups except for serum creatinine which was slightly higher in the C/F− group, due to one subject who was slightly dehydrated. His creatinine reached normal values after rehydration.
Changes in serum PTH levels for the four subgroups are illustrated over time on Fig. 1 . In the placebo group, a decrease in PTH was observed before the administration of furosemide in phase with the physiological diurnal variations of PTH [7] from (median; interquartile range (iqr)) 59. The injection of furosemide produced a sharp increase in plasma PTH levels in subjects under placebo (P/F+) from (median; iqr) 20.0 (16.0; 24.0) ng/l at H0 to 38.0 (33.0; 48.0) ng/l at H1 (p=0.001). The furosemide effect on PTH persisted during 3 h. In subjects preexposed to cinacalcet (C/F+ subgroup), the PTH response to furosemide did only change from 1.5 (1.5; 1.5) ng/l at H0 to 3.0 (1.5; 1.9) ng/l at H1 (p=0.071), whereas no PTH change was observed in furosemide-naive subjects, passing We measured the area under the curve (AUC) of plasma PTH between H0 and H6 in the four subgroups and found that subjects on placebo receiving furosemide showed significantly higher values as compared to other subgroups (Supplemental Fig. S1 ): (mean±SD) 1248±404 min ng/l in P/F+ vs 447± 319 min ng/l in C/F+ (p=0.003) and 320±273 min ng/l in P/F − (p=0.003 vs P/F+) and 452±363 min ng/l in C/F− (p=0.007 vs P/F+). This further demonstrates that furosemide stimulates PTH secretion in humans and that this effect was not observed under cinacalcet. To decipher the mechanisms underlying the increase of PTH levels induced by furosemide, variations in serum ionized calcium and in urinary calcium excretion were measured (Fig. 2 ). In the P/F+ group, no significant change in plasma ionized calcium was observed between baseline and the peak effect of furosemide (1.19±0.06 mmol/l at H0 and 1.19± 0.03 mmol/l at H1; mean±SD). In the C/F+ group, a decrease in plasma calcium was observed from 1.17±0.04 at H0 to 1.15±0.04 mmol/l at H1 (p=0.008) (Fig. 2a) . No significant change in ionized calcium was seen in participants who did not receive furosemide (groups C/F− and P/F−). Taken together, these results strongly suggest that the change in PTH concentration observed in the P/F+ group cannot be attributed to variations of serum calcium.
Furosemide induced a significant increase in urinary calcium excretion which was similar under cinacalcet or placebo (Fig. 2b) . No change in calciuria was found in subjects who did not receive furosemide. There was no relevant difference between subjects under cinacalcet and placebo, when comparing the subgroups exposed to furosemide (P/F+ vs C/F+, p=0.27) or between furosemide-naive subgroups (P/F− vs C/F−, p=0.50).
Plasma sodium and potassium profiles were comparable between the groups during the whole investigation day (supplemental Fig. S2 ). After furosemide injection, a slight but nonsignificant decrease in serum potassium was observed with no change in plasma sodium. Plasma phosphate and magnesium showed comparable values between subgroups and were not influenced by cinacalcet or furosemide treatments (data not shown). Figure 3a , b summarizes changes in urinary sodium and potassium over time. As expected, furosemide induced a sharp increase of urinary sodium and potassium excretion both under placebo and cinacalcet.
We further address the impact of cinacalcet and furosemide on plasma renin activity (PRA, Fig. 4a ) and plasma aldosterone levels (Fig. 4b) . Before the administration of furosemide, a parallel decrease of the two parameters was observed, probably due to the variation of the hydration status and the known circadian variations of these hormones.
In both P/F+ and C/F+ subgroups, furosemide induced a rapid and significant increase in plasma renin activity which peaked after 15 min.
In furosemide-naive groups, no difference between placebo or cinacalcet-treated groups and no change in PRA was observed. As shown in Fig. 4b , we have also investigated the changes in plasma aldosterone which followed a similar pattern as PRA. Again, no significant difference was found between P/F+ and C/F+, although in C/F+, plasma aldosterone levels tended to be lower at H0 and for the next 2 h.
Finally, we assessed whether parathyroid tissue expresses the furosemide-targeted transporters NKCC1 or NKCC2. Quantitative PCR was performed on reversed transcribed RNA obtained from parathyroid tissue of an excised adenoma.
PTH was strongly expressed as expected, as well as PTH receptor (PTHR1) and NKCC1, while NKCC2 was not detected (Fig. 5) .
Discussion
We showed here that an acute administration of the loop diuretic furosemide increases plasma PTH levels in healthy humans in the absence of any measurable changes in serum ionized calcium or other plasma electrolytes. The PTH response to furosemide was blunted by the previous administration of the calcimimetic cinacalcet despite a slight decrease in plasma ionized calcium induced by cinacalcet. In contrast to animal studies, cinacalcet does not appear to blunt the stimulatory effect of furosemide on renin secretion. However, plasma aldosterone levels were lower after administration of No significant change in ionized calcium values occurs in P/F+ subgroup, whereas a significant decrease is noted in C/F+ subgroup that suggests that PTH increase is not linked to plasma ionized calcium values. Both F+ groups show a significant acute increase in calciuria which does not occur in F− subgroups. P/F− placebo subgroup; C/F− cinacalcet subgroup; P/F+ placebo/furosemide subgroup; C/F+ cinacalcet/furosemide subgroup; Furosemide was injected at time 0. Values are means±SEM. *p<0.05 between P/F+ and P/F− subgroups. &p<0.05 between C/F+ and C/F− cinacalcet. And, the time course of PTH levels after furosemide correlated with the changes in PRA and aldosterone. Whether cinacalcet is mediating the effect of furosemide on PTH via renin-angiotensin-aldosterone system remains uncertain. At last, transient variations in plasma sodium and potassium do not appear to be associated with the change in PTH induced by furosemide.
Several hypotheses have been proposed to explain furosemide-induced PTH secretion. (i) By increasing calciuria and slightly decreasing calcemia, furosemide could stimulate PTH secretion in the parathyroid gland [8] .
(ii) Following furosemide injection, volume depletion and stimulation of the renin-angiotensin-aldosterone system could lead to increased PTH secretion by mechanisms not yet well understood [3, 9, 11] . (iii) Furosemide, by changing plasma potassium levels, could interfere with the Na + /K + -APTase activity, which is known to regulate PTH secretion in the parathyroid tissue [2] . (iv) Finally, furosemide could act directly on the parathyroid glands and stimulate PTH secretion.
In previously published papers describing the ability of furosemide to stimulate PTH [28, 10] , the more simple hypothesis was that the increase in calciuria provoked by furosemide through its action on Henle's loop would lead to found that in an anuric patient, furosemide had no effect on PTH [27] . In addition, the administration of hydrochlorothiazide, which reduces urinary calcium excretion, was not associated with any change in PTH [31] . However, total as well as ionized plasma calcium levels remained unchanged after furosemide administration in these studies. A similar observation was made in our study in which we found a clear stimulation of PTH and hypercalciuria after furosemide treatment, but without any detectable change in serum ionized calcium. This suggests that calcemia may not be the link between calciuria and PTH release, unless very rapid and transient variations in calcemia occur and are under the detection threshold of our protocol. This could be the case if an immediate pool of calcium is mobilized from the bone, as suggested by some authors [26] . Against a prominent role of serum calcium stands our observation that in the cinacalcet group, PTH release after furosemide is blunted despite a rise in urinary calcium excretion and a decrease in plasma ionized calcium. The finding that a single dose of the calcimimetic cinacalcet given 3 h before furosemide almost abolishes the PTH response to furosemide suggests that calcium sensing is, to some degree, involved in the response to furosemide but does not allow concluding on the precise role of calcium. We investigated the interaction between furosemide, PTH, and the renin-angiotensin-aldosterone system and evaluated the role of CaSR. Indeed, calcium-sensing receptors are expressed in juxtaglomerular cells in mice [23] and rats [18] . Recent findings in humans indicate that there is a tight link between the RAAS and the parathyroid glands, suggesting that the RAAS may mediate the furosemide effect on PTH secretion [4, 15, 16, 19, 20, 22, 29] . In a previous experimental study, we demonstrated that administration of the calcimimetic RS568 inhibited renin secretion in rats and blunted the renin response induced by furosemide [18] . The calcimimetic also blunted the PTH response to furosemide. For these reasons, we have investigated the impact of cinacalcet on the renin response to furosemide and whether renin or aldosterone could be mediators of the furosemide effect on PTH release. In contrast to what was observed in the rat, cinacalcet did not inhibit the renin response to furosemide in our healthy subjects. Of note however, a strong positive association between PTH and renin, as evidenced by the similar kinetic of the hormones along the study procedure, was observed with an interesting synchronous course after furosemide injection. A similar synchrony was found between aldosterone and PTH, with a slight delay [9, 3] . These observations could have led to the speculation of a possible implication of the RAAS in the furosemide-mediated PTH response. But, in calcimimetic-receiving subjects, renin and aldosterone responses to furosemide were intact excluding renin and aldosterone as a mediator of the furosemide effect. Regarding the possible role of aldosterone, the situation is however more complex. Indeed, plasma aldosterone levels were lower upon administration of cinacalcet and remained lower after the injection of furosemide. Whether the reduction in plasma aldosterone induced by cinacalcet has contributed to the blunting of PTH in the C/F+ group is thus possible but not ascertained by our data.
Looking for other mechanisms mediating the furosemide increase in PTH, we explored the role of changes in serum electrolytes namely sodium, potassium, magnesium, and phosphate. Brown et al. have shown in vitro that hypokalemia and the exposure to ouabain, a specific inhibitor of the Na + -K + ATPase, inhibited PTH secretion in isolated bovine parathyroid cells [1, 2] . More recently, Imura [14] demonstrated the involvement of α-klotho in calcium-dependent trafficking of the Na + -K + ATPase to the cell surface of the parathyroid gland's chief cells. These results suggest that the electrochemical gradient created by the klotho-dependent increase in cell surface expression of the Na + -K + ATPase participates in the regulation of PTH secretion. This pathway is disrupted either in state of α-klotho deficiency or in case of ouabain exposure. Thus, hypokalemia may be associated with PTH secretion through the action of Na + -K + ATPase. However, more recent data in rats questioned the regulating action of Na + -K + ATPase on parathyroid activity [21] . In our study, no significant change in plasma sodium and magnesium were found, thus excluding a role of these electrolytes. A trend toward lower potassium levels was noted but was of similar magnitude between placebo-and cinacalcet-treated subjects, rejecting a major role of hypokalemia and of the Na Finally, furosemide may act directly on the parathyroid gland tissue, given that sodium-potassium-chloride cotransporters (NKCCs) are ubiquitously expressed. No evidence supporting this hypothesis has been provided so far, but we demonstrated here that the parathyroid tissue expresses NKCC1 mRNA, but not the kidney-specific gene NKCC2. This raises the possibility of a direct role of furosemide acting on the parathyroid gland, as previously shown for the juxtaglomerular apparatus by Castrop et al. [5] . NKCC1 has a Ki for furosemide in the micromolar range, compatible with plasma concentrations that can be rapidly reached after furosemide injection [12] . Further experiments testing this hypothesis need now to be conducted.
Limitations of this study include the low number of volunteers, however reaching the calculated number for full power analysis, and the lack of measurement of 1,25 (OH) 2 -vitamin D. The fact that cinacalcet inhibited PTH to very low levels rendered the interpretation of the data more delicate, particularly with regard to PTH stimulation. However, we feel that even if cinacalcet significantly reduced PTH levels, the overall conclusions of the study are not affected.
In conclusion, the furosemide-induced acute increase of PTH (doubling in less than 15 min) was ascertained in humans by this study. If the mechanism behind this observation remains unclear, we provide here insights in several working hypotheses. First, we did not observe changes in plasma calcium levels, excluding hypocalcemia as the main trigger for PTH increase. Second, we did not observe a clear correlation between the RAAS and PTH increase, suggesting only weak interaction between the two systems during furosemide stimulation in humans. Third, we did not identify any change in plasma electrolytes that could influence Na + /K + -ATPase function involved in abnormal PTH secretion. Fourth, we show that human parathyroid tissue expresses the furosemide-target gene NKCC1, which may modulate PTH secretion. Finally, we showed that furosemide-induced PTH secretion is dependent upon calcium-sensing receptor function. This further emphasizes the role of CaSR at the interface between both calcium and sodium regulatory systems.
